Back to Studies

Study analysis · PLOS One · 2025

Huntington's disease has no disease-modifying treatment — now scientists want to test if simply changing when you eat could slow it down, but the study hasn't even finished yet.

This is a plan for a 12-week study to see if people with early Huntington's disease can safely eat only within a 6-8 hour window each day; no results exist yet.

Reading level
Low certainty
Level 2b · Individual cohort studyAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study is like trying a new diet on a small group of people without a comparison group. It can tell us if people can stick to the diet and if it seems safe, but it can't prove the diet actually helps with the disease because there's no group who didn't do the diet to compare against.

What’s the bottom line?

This is a plan for a study, not the results. Researchers will ask 25 people with early Huntington's disease to eat only within a 6–8 hour window every day for 12 weeks. They want to see if people can stick to it and if it is safe.

How strong is this study?

The study is carefully planned with lots of measurements and safety checks, but it's small and everyone knows they're on the diet, which can make them feel better just because they expect to. So the results will help plan bigger studies, but they aren't strong enough to prove the diet works.

Reporting

35 / 100

  • COI disclosureconflicts of interest not disclosed
  • Data availability+35/35
  • Code availabilitycode not shared
Methodology

15 / 100

  • Randomizationnot randomized
  • Blindingnot blinded
  • Control groupno control group
  • Sample size (n=25)+2.4/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

46 / 100

  • P-valuesno p-values reported
  • Effect sizeno effect size reported
  • Confidence intervals+15/15
  • Pre-registration+15/15

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Cohort Studies
Level 2b
44

44 / 100

Probability of being correct

Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.

This design cannot establish causation — the findings describe an association, not a cause. This is a single-arm, open-label, uncontrolled pilot study with no randomization and no comparator group. Any pre-post changes could be due to natural disease progression, regression to the mean, placebo effects, expectancy, or confounding. Therefore, it cannot establish a cause-effect relationship between time-restricted eating and any clinical or biomarker outcome.

COI Unknown

Could not determine conflict of interest status

Not Disclosed

No conflict of interest or funding information was provided in the available text, so conflicts cannot be assessed.

Undisclosed — Suspicious

The provided text is an excerpt of a clinical trial protocol and lacks an author list, affiliations, funding statement, and conflict of interest declaration. Therefore, no COI assessment can be made from the available information.

Key takeaways

  1. 01

    No results yet.

  2. 02

    The study plans to enroll 25 participants, use a 12-week time-restricted eating window of 6–8 hours, and consider the diet feasible if at least 80% of participants stick to it on at least 80% of days.

  3. 03

    No effect sizes are available.

  4. 04

    Because no results have been collected, there is no absolute risk or benefit to contextualize.

  5. 05

    This protocol cannot yet show whether time-restricted eating helps, harms, or does nothing for people with Huntington's disease.

Surprising findings

  • No clinical trial has ever tested time-restricted eating in Huntington's disease before this protocol.Given how much animal and non-HD human data exist, you might assume someone had already run a human study in HD. They haven't.
  • The researchers explicitly say they do not expect statistically significant clinical changes in this short, small study.Most trial announcements sound hopeful about clinical benefit. This protocol is unusually candid that the main goal is feasibility and safety, not proving the diet works.
  • Participants can self-select their eating window timing, even though early vs. delayed TRE may have different circadian effects.You might expect a trial to standardize timing to reduce noise. Instead, the authors prioritize real-world feasibility and social routine.

Practical takeaways

Do not start time-restricted eating specifically to treat Huntington's disease based on this study — there are no results yet.

This is only a protocol. No human efficacy or safety outcomes in HD have been reported.

high confidence

If you or a loved one joins an HD diet trial, track weight and fat-free mass carefully and report any unintended weight loss to the study team.

The 10% body-weight-loss stopping rule is specific to this trial, not general medical advice.

high confidence

For general healthy aging, a 6-week randomized crossover trial in midlife and older adults found TRE had no influence on body mass, fat-free mass, bone density, or nutrient intake — but that was not in Huntington's disease.

That trial was short, in healthy older adults, and does not prove long-term safety in neurodegenerative disease.

medium confidence

When you see headlines about fasting and brain disease, check whether the study is a protocol, an animal study, a case report, or a controlled human trial.

This study is a protocol, so any headline claiming it shows benefit is premature.

high confidence

Why this study matters

A diet trial for Huntington's — but only a protocol

This is not a results paper. It proposes a 12-week, open-label, single-arm pilot study in 25 participants with late prodromal or early manifest Huntington's disease. The primary outcome is feasibility: at least 80% of participants adhering to a 6-8 hour eating window on at least 80% of trial days. No effect sizes or absolute risk estimates are reported because no outcomes have been collected.

Huntington's is a devastating genetic brain disease with no cure. A simple, free lifestyle change like time-restricted eating would be huge — but we have zero human results yet.

The 80/80 feasibility bar

The study will call time-restricted eating 'feasible' if ≥80% of participants can eat within a 6-8 hour window on ≥80% of the 12-week trial days. Adherence is tracked by self-report and time-stamped meal logs, with photo-based app tracking twice per week. This is a strict but common pilot-study threshold.

It shows how scientists define success before they even run the study. Most people think trials are about whether a treatment works; this one first asks whether people can actually stick to it.

Safety fear: weight loss in Huntington's disease

HD is known for causing weight loss, especially in later stages. Time-restricted eating is often associated with weight loss, mostly in overweight or obese people and largely due to eating fewer calories. The protocol monitors body composition and will stop the diet if a participant loses more than 10% of total body weight.

A diet that helps most people could be dangerous for a disease where weight loss is already a problem. This is a real safety tension.

Blood biomarkers NfL and GFAP as early signals

Secondary outcomes include plasma neurofilament light protein (NfL) and glial fibrillary acidic protein (GFAP), markers of neurodegeneration. The power calculation says n=20 gives 90% power to detect a 15% relative change in plasma NfL, assuming a standard deviation of 0.65 log pg/ml. No absolute risk or clinical benefit is reported.

These blood markers are increasingly used in brain disease research. If a simple diet changes them, that could be a fast signal — but it's still not proof of clinical benefit.

Mice, one man, and a missing human trial

In HD animal models, time-restricted eating has been reported to increase clearance of mutant huntingtin protein, reduce inclusions, improve motor function, extend lifespan, and improve circadian rhythm. A single case report described a 41-year-old man with HD who improved on a 48-week combined TRE plus ketogenic diet. But no controlled human trial has tested TRE in HD until this protocol.

The gap between animal evidence and human reality is enormous. One case report is not evidence of efficacy.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.

Standing

The people behind it

The researchers who wrote the study this analysis is built on.

Authored by

4 researchers

If this is your work, this is how we attribute it on Fit Body Science. Russell G. Wells is listed as the lead author.